{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T18:23:45Z","timestamp":1767983025161,"version":"3.49.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,29]]},"DOI":"10.7759\/cureus.95693","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T18:42:28Z","timestamp":1761763348000},"source":"Crossref","is-referenced-by-count":1,"title":["Severe Rhabdomyolysis in an Elderly Patient With Diabetes and Vascular Disease: Interplay of Statin Therapy, Sodium-Glucose Cotransporter-2 (SGLT2) Inhibition, and Thiazide-Induced Hypokalemia"],"prefix":"10.7759","author":[{"given":"Darpan","family":"Kothia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bola","family":"Habeb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix","family":"Ermolenko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2021.09.025","article-title":"Rhabdomyolysis: A syndrome to be considered. (Article in Spanish)","volume":"158","author":"Baeza-Trinidad R","year":"2022","unstructured":"Baeza-Trinidad R. Rhabdomyolysis: A syndrome to be considered. (Article in Spanish). Med Clin (Barc). 2022, 158:277-83. 10.1016\/j.medcli.2021.09.025","journal-title":"Med Clin (Barc)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1097\/JOM.0000000000002351","article-title":"Prevention of occupational heat-related illnesses","volume":"63","author":"Tustin A","year":"2021","unstructured":"Tustin A, Sayeed Y, Berenji M, et al.. Prevention of occupational heat-related illnesses. J Occup Environ Med. 2021, 63:e737-44. 10.1097\/JOM.0000000000002351","journal-title":"J Occup Environ Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0801327","article-title":"Rhabdomyolysis and acute kidney injury","volume":"361","author":"Bosch X","year":"2009","unstructured":"Bosch X, Poch E, Grau JM. Rhabdomyolysis and acute kidney injury. N Engl J Med. 2009, 361:62-72. 10.1056\/NEJMra0801327","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/mus.24606","article-title":"Diagnostic evaluation of rhabdomyolysis","volume":"51","author":"Nance JR","year":"2015","unstructured":"Nance JR, Mammen AL. Diagnostic evaluation of rhabdomyolysis. Muscle Nerve. 2015, 51:793-810. 10.1002\/mus.24606","journal-title":"Muscle Nerve"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2021.04.007","article-title":"Risk factors and future directions for preventing and diagnosing exertional rhabdomyolysis","volume":"31","author":"Carneiro A","year":"2021","unstructured":"Carneiro A, Viana-Gomes D, Macedo-da-Silva J, et al.. Risk factors and future directions for preventing and diagnosing exertional rhabdomyolysis. Neuromuscul Disord. 2021, 31:583-95. 10.1016\/j.nmd.2021.04.007","journal-title":"Neuromuscul Disord"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/omcr\/omx104","article-title":"Statin-induced rhabdomyolysis: A complication of a commonly overlooked drug interaction","volume":"2018","author":"Ezad S","year":"2018","unstructured":"Ezad S, Cheema H, Collins N. Statin-induced rhabdomyolysis: A complication of a commonly overlooked drug interaction. Oxf Med Case Reports. 2018, 2018:omx104. 10.1093\/omcr\/omx104","journal-title":"Oxf Med Case Reports"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2147\/DHPS.S333738","article-title":"A narrative review of statin-induced rhabdomyolysis: Molecular mechanism, risk factors, and management","volume":"13","author":"Safitri N","year":"2021","unstructured":"Safitri N, Alaina MF, Pitaloka DA, Abdulah R. A narrative review of statin-induced rhabdomyolysis: Molecular mechanism, risk factors, and management. Drug Healthc Patient Saf. 2021, 13:211-9. 10.2147\/DHPS.S333738","journal-title":"Drug Healthc Patient Saf"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.46641","article-title":"Rhabdomyolysis and sodium-glucose-linked transport inhibitors in patients taking statins","volume":"7","author":"Harel Z","year":"2024","unstructured":"Harel Z, Jeyakumar N, Smith G, Ray JG, Clemens KK, Juurlink DN. Rhabdomyolysis and sodium-glucose-linked transport inhibitors in patients taking statins. JAMA Netw Open. 2024, 7:e2446641. 10.1001\/jamanetworkopen.2024.46641","journal-title":"JAMA Netw Open"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.25259\/IJN_25_2024","article-title":"Severe rhabdomyolysis due to presumed drug interactions of dapagliflozin with rosuvastatin: A case report","volume":"35","author":"Udayashankar A","year":"2025","unstructured":"Udayashankar A, Mukherjee T, George K, KrishneGowda K. Severe rhabdomyolysis due to presumed drug interactions of dapagliflozin with rosuvastatin: A case report. Indian J Nephrol. 2025, 35:557-9. 10.25259\/IJN_25_2024","journal-title":"Indian J Nephrol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15711","article-title":"Concomitant use of statins and sodium-glucose co-transporter 2 inhibitors and the risk of myotoxicity reporting: A disproportionality analysis","volume":"89","author":"Gravel CA","year":"2023","unstructured":"Gravel CA, Krewski D, Mattison DR, Momoli F, Douros A. Concomitant use of statins and sodium-glucose co-transporter 2 inhibitors and the risk of myotoxicity reporting: A disproportionality analysis. Br J Clin Pharmacol. 2023, 89:2430-45. 10.1111\/bcp.15711","journal-title":"Br J Clin Pharmacol"},{"key":"ref11","article-title":"Rhabdomyolysis due to diuretic treatment","volume":"44","author":"Antoniadis DJ","year":"2003","unstructured":"Antoniadis DJ, Vavouranakis EM, Tsioufis KP, Toutouzas PK. Rhabdomyolysis due to diuretic treatment. Hellenic J Cardiol. 2003, 44:80-2.","journal-title":"Hellenic J Cardiol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.11909\/j.issn.1671-5411.2018.04.005","article-title":"A rare case of hypokalemia-induced rhabdomyolysis","volume":"15","author":"He R","year":"2018","unstructured":"He R, Guo WJ, She F, et al.. A rare case of hypokalemia-induced rhabdomyolysis. J Geriatr Cardiol. 2018, 15:321-4. 10.11909\/j.issn.1671-5411.2018.04.005","journal-title":"J Geriatr Cardiol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2021.1921735","article-title":"Potential drug-drug interaction between sodium-glucose co-transporter 2 inhibitors and statins: Pharmacological and clinical evidence","volume":"17","author":"Lalagkas PN","year":"2021","unstructured":"Lalagkas PN, Poulentzas G, Kontogiorgis C, Douros A. Potential drug-drug interaction between sodium-glucose co-transporter 2 inhibitors and statins: Pharmacological and clinical evidence. Expert Opin Drug Metab Toxicol. 2021, 17:697-705. 10.1080\/17425255.2021.1921735","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref14","unstructured":"U.S. Food and Drug Administration. Empagliflozin (Jardiance) NDA 204629, Clinical Pharmacology Review. (2025). Accessed. September 14, 2025: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2020\/204629Orig1s008.pdf."},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo CA","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, et al.. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981, 30:239-45. 10.1038\/clpt.1981.154","journal-title":"Clin Pharmacol Ther"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2003.04.053","article-title":"Elevated serum cardiac troponin I in rhabdomyolysis","volume":"96","author":"Punukollu G","year":"2004","unstructured":"Punukollu G, Gowda RM, Khan IA, Mehta NJ, Navarro V, Vasavada BC, Sacchi TJ. Elevated serum cardiac troponin I in rhabdomyolysis. Int J Cardiol. 2004, 96:35-40. 10.1016\/j.ijcard.2003.04.053","journal-title":"Int J Cardiol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.86199","article-title":"From cholesterol control to critical illness: A case of statin-associated rhabdomyolysis with concurrent acute kidney injury and hepatotoxicity","volume":"17","author":"Habeb B","year":"2025","unstructured":"Habeb B, Khair S, Fowler S. From cholesterol control to critical illness: A case of statin-associated rhabdomyolysis with concurrent acute kidney injury and hepatotoxicity. Cureus. 2025, 17:e86199. 10.7759\/cureus.86199","journal-title":"Cureus"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology\/American Heart Association Task\u00a0Force\u00a0on\u00a0Clinical Practice Guidelines","volume":"73","author":"Grundy SM","year":"2019","unstructured":"Grundy SM, Stone NJ, Bailey AL, et al.. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology\/American Heart Association Task\u00a0Force\u00a0on\u00a0Clinical Practice Guidelines. J Am Coll Cardiol. 2019, 73:e285-350. 10.1016\/j.jacc.2018.11.003","journal-title":"J Am Coll Cardiol"},{"key":"ref19","unstructured":"Crestor. Food and Drug Administration. Updated date. 2024-07-31. (2024). Accessed: January 31, 2024: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/021366s046lbl.pdf."},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab175","article-title":"Corrigendum to: \"Lipid management in patients with endocrine disorders: An Endocrine Society Clinical Practice Guideline\"","volume":"106","year":"2021","unstructured":"Corrigendum to. \"Lipid management in patients with endocrine disorders: An Endocrine Society Clinical Practice Guideline\". J Clin Endocrinol Metab. 2021, 106:e2465. 10.1210\/clinem\/dgab175","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/420914-severe-rhabdomyolysis-in-an-elderly-patient-with-diabetes-and-vascular-disease-interplay-of-statin-therapy-sodium-glucose-cotransporter-2-sglt2-inhibition-and-thiazide-induced-hypokalemia","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T18:42:32Z","timestamp":1761763352000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/420914-severe-rhabdomyolysis-in-an-elderly-patient-with-diabetes-and-vascular-disease-interplay-of-statin-therapy-sodium-glucose-cotransporter-2-sglt2-inhibition-and-thiazide-induced-hypokalemia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,29]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.95693","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,29]]}}}